Cogent Biosciences Inc
Research Cogent Biosciences Inc (COGT) on Bullrun: market cap USD 6.29B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCOGT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.29B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 97.35M
- Free cash flow-USD 286.27M
Valuation Snapshot
latest market cap is USD 6.29B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 328.94M | -USD 266.00M | n/a | -2.16 | USD 312.01M | USD 222.90M | USD 636.37M |
| FY2024 | USD 0 | -USD 255.86M | -USD 208.36M | n/a | -1.94 | USD 98.17M | USD 0 | USD 256.29M |
| FY2023 | n/a | -USD 192.41M | -USD 156.42M | n/a | -1.94 | USD 53.23M | USD 18.85M | USD 257.80M |
| FY2022 | n/a | -USD 140.24M | -USD 125.50M | n/a | -1.73 | USD 139.89M | USD 28.07M | USD 255.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.29B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.72B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 861.60M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 506.41M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 807.97M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 375.85M | n/a | n/a | n/a |
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cogent Biosciences Inc's market cap?
Cogent Biosciences Inc's market capitalization is USD 6.29B.
What does Cogent Biosciences Inc do?
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.